RSV Immunisations 2024

Description

The provision of immunisation products indicated for the prevention or protection from Respiratory Syncytial Virus (RSV) lower respiratory tract disease Lot 1: A monoclonal antibody for infants The provision of a product indicated for the prevention or protection from Respiratory Syncytial Virus (RSV) in infants from birth, including pre-term infants, weighing less than 5 kilograms by direct passive immunisation of the infant by means of a monoclonal antibody. The contracting authority estimates their requirement for deliveries between 1 July 2024 and 30 June 2026 ('Initial Term') of the contract to be up to 1.6 million doses, with the option to extend for up to an additional 24 months. Lot 4: A vaccine for older adults (annual cohort and a catch-up volume) The provision of a product indicated for the prevention or protection from Respiratory Syncytial Virus (RSV) in a routine single annual cohort of older adults with a catch up for multiple cohorts in the first year. The contracting authority estimates their requirement for deliveries between 1 July 2024 and 30 June 2026 ('Initial Term') of the contract to be up to 4 million doses, with the option to extend for up to an additional 24 months. Lot 3: A vaccine for older adults (annual cohort) The provision of a product indicated for the prevention or protection from Respiratory Syncytial Virus (RSV) in a routine single annual cohort of older adults. The contracting authority estimates their requirement for deliveries between 1 July 2024 and 30 June 2026 ('Initial Term') of the contract to be up to 1.45 million doses, with the option to extend for up to an additional 24 months. Lot 2: A vaccine which provides maternal protection The provision of a product indicated for the prevention or protection from RSV in infants by means of a vaccination given to pregnant women. The contracting authority estimates their requirement for deliveries between 1 July 2024 and 30 June 2026 ('Initial Term') of the contract to be up to 1.69 million doses, with the option to extend for up to an additional 24 months.